Publikationen (25) Publikationen von LAURA BASTERRETXEA BADIOLA

2024

  1. Identification of miRNAs and Their Target Genes Associated with Sunitinib Resistance in Clear Cell Renal Cell Carcinoma Patients

    International Journal of Molecular Sciences, Vol. 25, Núm. 13

2023

  1. Zahartzea, ikerketa medikoen ikuspegitik

    Elhuyar: zientzia eta teknika, Núm. 352, pp. 28-33

2022

  1. Prediction of chemotoxicity, unplanned hospitalizations and early death in older patients with colorectal cancer treated with chemotherapy

    Cancers, Vol. 14, Núm. 1

2021

  1. Development and validation of an early mortality risk score for older patients treated with chemotherapy for cancer

    Journal of Clinical Medicine, Vol. 10, Núm. 8

  2. Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial

    Nature Communications, Vol. 12, Núm. 1

  3. Prediction of unplanned hospitalizations in older patients treated with chemotherapy

    Cancers, Vol. 13, Núm. 6, pp. 1-11

  4. Predictive factors for simultaneous distant metastasis in head and neck cancer patients during the diagnostic work-up

    European Archives of Oto-Rhino-Laryngology, Vol. 278, Núm. 11, pp. 4483-4489

  5. Preferences for Renal Cell Carcinoma Pharmacological Treatment: A Discrete Choice Experiment in Patients and Oncologists

    Frontiers in Oncology, Vol. 11

  6. Undertreatment and overtreatment in older patients treated with chemotherapy

    Journal of Geriatric Oncology, Vol. 12, Núm. 3, pp. 381-387

2020

  1. Online farmazia-arreta onkologiaren arloan: eredu pilotu berriak garatzen

    Osagaiz: osasun-zientzien aldizkaria, Vol. 4, Núm. 1, pp. 29-38

  2. Predicting Chemotherapy Toxicity in Older Patients with Cancer: A Multicenter Prospective Study

    Oncologist, Vol. 25, Núm. 10, pp. e1516-e1524

2019

  1. SEOM clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2018)

    Clinical and Translational Oncology, Vol. 21, Núm. 1, pp. 64-74

  2. Sunitinib rechallenge in advanced renal cell carcinoma: outcomes of a multicenter retrospective study

    Cancer Chemotherapy and Pharmacology, Vol. 84, Núm. 4, pp. 781-789

2018

  1. Systematic review and survival meta-analysis of real world evidence on first-line pazopanib for metastatic renal cell carcinoma

    Critical Reviews in Oncology/Hematology, Vol. 121, pp. 45-50

2017

  1. A Prospective Observational Study for Assessment and Outcome Association of Circulating Endothelial Cells in Clear Cell Renal Cell Carcinoma Patients Who Show Initial Benefit from First-line Treatment. The CIRCLES (CIRCuLating Endothelial cellS) Study (SOGUG-CEC-2011-01)

    European Urology Focus, Vol. 3, Núm. 4-5, pp. 430-436

  2. Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma

    Oncotarget, Vol. 8, Núm. 18, pp. 30410-30421

2016

  1. Epicure: A European epidemiological study of patients with an advanced or metastatic Urothelial Carcinoma (UC) having progressed to a platinum-based chemotherapy

    BMC Cancer, Vol. 16, Núm. 1

  2. Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study

    BMC Cancer, Vol. 16, Núm. 1

  3. Validation of the international metastatic renal-cell carcinoma database consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: The Spanish oncologic genitourinary group (SOGUG) SPAZO study

    Annals of Oncology, Vol. 27, Núm. 4, pp. 706-711

2006

  1. Gastrointestinal stromal tumors presenting as pelvic masses

    Gastroenterologia y Hepatologia, Vol. 29, Núm. 8, pp. 447-450